1. Home
  2. DMRC vs NERV Comparison

DMRC vs NERV Comparison

Compare DMRC & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digimarc Corporation

DMRC

Digimarc Corporation

HOLD

Current Price

$7.22

Market Cap

174.3M

Sector

Technology

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$2.30

Market Cap

166.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMRC
NERV
Founded
2008
2007
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.3M
166.4M
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
DMRC
NERV
Price
$7.22
$2.30
Analyst Decision
Hold
Buy
Analyst Count
2
3
Target Price
★ $11.50
$10.33
AVG Volume (30 Days)
★ 147.9K
105.4K
Earning Date
11-06-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.99
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.07
$2.24
52 Week High
$17.47
$8.80

Technical Indicators

Market Signals
Indicator
DMRC
NERV
Relative Strength Index (RSI) 61.53 27.35
Support Level $7.06 N/A
Resistance Level $8.20 $5.69
Average True Range (ATR) 0.46 0.26
MACD 0.11 -0.02
Stochastic Oscillator 61.17 4.83

Price Performance

Historical Comparison
DMRC
NERV

About DMRC Digimarc Corporation

Digimarc Corp is a product digitization company delivering business value across industries through identities and cloud-based solutions. Its solutions are Anti-counterfeiting, Internal Compliance, Leak Detection, Piracy Prevention, Product Swap Prevention, Provenance & Authenticity (C2PA), Recycling, and Royalty Monitoring. The group offers services to various industries such as Consumer Packaged Goods, Government, Media, Pharmaceutical, and Retail.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: